Small intestinal metabolism is central to whole-body insulin resistance.
Adult
Animals
Area Under Curve
Biliopancreatic Diversion
Blood Glucose
/ metabolism
C-Peptide
/ blood
Cells, Cultured
Gastric Bypass
Glucagon-Like Peptide 1
/ blood
Gluconeogenesis
Glucose
/ metabolism
Glucose Tolerance Test
Hepatocytes
Humans
Insulin
/ metabolism
Insulin Resistance
Jejunum
/ metabolism
Liver
/ metabolism
Mice
Middle Aged
Muscle, Skeletal
/ physiology
Myoblasts
Obesity
/ surgery
Phosphorylation
Plasma
Postoperative Period
Preoperative Period
Proto-Oncogene Proteins c-akt
/ metabolism
Swine
diabetes mellitus
small intestine
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
03
06
2020
revised:
14
07
2020
accepted:
24
07
2020
pubmed:
1
10
2020
medline:
12
1
2022
entrez:
30
9
2020
Statut:
ppublish
Résumé
To assess the role of jejunum in insulin resistance in humans and in experimental animals. Twenty-four subjects undergoing biliopancreatic diversion (BPD) or Roux-en-Y gastric bypass (RYGB) were enrolled. Insulin sensitivity was measured at baseline and at 1 week after surgery using oral glucose minimal model.We excluded the jejunum from intestinal continuity in pigs and created a jejunal loop with its vascular and nerve supply intact accessible from two cutaneous stomas, and reconnected the bowel with an end-to-end anastomosis. Glucose stable isotopes were given in the stomach or in the jejunal loop.In vitro studies using primary porcine and human hepatocytes or myoblasts tested the effects of plasma on gluconeogenesis or glucose uptake and insulin signalling. Whole-body insulin sensitivity (S Proximal gut plays a crucial role in controlling insulin sensitivity through a distinctive metabolic signature involving hepatic gluconeogenesis and muscle insulin resistance. Bypassing the jejunum is beneficial in terms of insulin-mediated glucose disposal in obesity. NCT03111953.
Identifiants
pubmed: 32994312
pii: gutjnl-2020-322073
doi: 10.1136/gutjnl-2020-322073
doi:
Substances chimiques
Blood Glucose
0
C-Peptide
0
Insulin
0
Glucagon-Like Peptide 1
89750-14-1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Glucose
IY9XDZ35W2
Banques de données
ClinicalTrials.gov
['NCT03111953']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1098-1109Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.